Unlock stock picks and a broker-level newsfeed that powers Wall Street.
LSE - Delayed Quote USD

BioPharma Credit PLC (BPCR.L)

Compare
0.8720
-0.0140
(-1.58%)
At close: 4:35:29 PM GMT+1
Loading Chart for BPCR.L
  • Previous Close 0.8860
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.9400
  • Volume 0
  • Avg. Volume 1,078,315
  • Market Cap (intraday) 988.761M
  • Beta (5Y Monthly) 0.14
  • PE Ratio (TTM) 0.09
  • EPS (TTM) 0.1000
  • Earnings Date Mar 25, 2025
  • Forward Dividend & Yield 0.07 (7.90%)
  • Ex-Dividend Date Apr 3, 2025
  • 1y Target Est --

BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.

www.bpcruk.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BPCR.L

View More

Performance Overview: BPCR.L

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

BPCR.L
4.17%
FTSE 100 (^FTSE)
3.69%

1-Year Return

BPCR.L
8.89%
FTSE 100 (^FTSE)
6.77%

3-Year Return

BPCR.L
9.76%
FTSE 100 (^FTSE)
12.43%

5-Year Return

BPCR.L
46.43%
FTSE 100 (^FTSE)
56.49%

Compare To: BPCR.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BPCR.L

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    1.00B

  • Enterprise Value

    --

  • Trailing P/E

    8.87

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.70

  • Price/Book (mrq)

    0.85

  • Enterprise Value/Revenue

    8.06

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    81.44%

  • Return on Assets (ttm)

    5.97%

  • Return on Equity (ttm)

    9.69%

  • Revenue (ttm)

    150.03M

  • Net Income Avi to Common (ttm)

    122.18M

  • Diluted EPS (ttm)

    0.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.62M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    66.9M

Research Analysis: BPCR.L

View More

Company Insights: BPCR.L

Research Reports: BPCR.L

View More

People Also Watch